Articles examine oral GLP-1 drugs, Novo Nordisk’s pipeline and GLP-1 addiction research. Other essays cover Ozempic and food spending and Novo Nordisk’s market decline. The IsoDDE analysis examines AI drug discovery.
Medicine
Medicine articles examine GLP-1 drugs, oral semaglutide and AI drug discovery, including IsoDDE.
- AI Can Now Design Drugs in Seconds; We Still Can't Tell You If They Work.
IsoDDE doubles AlphaFold 3 on hard benchmarks and beats physics-based gold standards. But no AI drug has FDA approval. What $4B in pharma deals actually mean.
- GLP-1 Receptor Agonists in ASUD Treatment
A phase 2 RCT shows low-dose semaglutide reduces alcohol craving and heavy drinking with effect sizes exceeding naltrexone. What GLP-1 means for AUD treatment.
- Novo Nordisk's Post-Patent Strategy
Novo Nordisk's lead replacement candidate amycretin reported Phase 1 data in The Lancet. How the company is positioning around the 2031 Ozempic patent cliff.
- Novo Was Europe's Most Valuable Company
Novo Nordisk lost 75% since June 2024. CagriSema failed vs Zepbound, US pricing is resetting lower, and Lilly leads on every axis. Full breakdown with numbers.
- Ozempic is Reshaping the Fast Food Industry
Cornell research: GLP-1 users cut grocery spending 5.3%, fast food 8%. With 16% household adoption and savory snacks down 10%, food stocks face headwinds.
- Why Lilly's Weight Loss Pill Isn't a Peptide
Oral semaglutide destroys 99% of its active ingredient per dose. Lilly's Foundayo skips the problem entirely. Inside the $70B oral GLP-1 pill race.